AZN Drops After Pausing COVID-19 Vaccine Trials

The equity is up over 24% year-over-year, however

Digital Content Manager
Sep 9, 2020 at 10:58 AM
facebook X logo linkedin

The shares of AstraZeneca plc (NYSE: AZN) are down 1.4% at $53.92 at last check, after the company suspended global trials of its experimental coronavirus vaccine after a participant presented an unexplained illness. AstraZeneca officials said in a statement an independent committee will review safety data, and that this is a routine action to ensure trial integrity. They also added they are working to minimize potential impacts on delivery timeline.

The security has been cooling off over the past couple of weeks. Though shares previously surged to an all-time high of $64.94 on July 20, the stock has been fighting overhead pressure at the $58 level for the last two months. Now, the security is dropping further below that level, with the once supportive 60-day moving average recently coming in as ceiling. Nonetheless, AZN is still up 24.3% year-over-year.

Analysts are optimistic towards AstraZeneca stock, with five of the six in coverage sporting a "strong buy," and only one carrying a tepid "hold" rating. Meanwhile, the equity's 12-month consensus target price of $59.10 is a 10% premium to current levels.

That optimism is echoed in the options pits, where calls are popular. The security sports a 10-day call/put volume ratio of 12.86 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits in the 78th percentile of its annual range. This suggests a healthier-than-usual appetite for bullish bets of late.

Traders looking to speculate on AstraZeneca stock's near-term trajectory should consider options. The security's Schaeffer's Volatility Index (SVI) of 33% sits in the 25th percentile of its annual range, suggesting short-term options are pricing in relatively low volatility expectations. In other words, the stock's near-term options are attractively priced at the moment.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI